CYTOKINETICS INCORPOR

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

03 Apr 2023 16:00:00 By Nasdaq GlobeNewswire

Cytokinetics Announces COURAGE-ALS Met Criteria for Futility at Second Interim Analysis

31 Mar 2023 07:30:00 By Nasdaq GlobeNewswire

Cytokinetics Releases Inaugural Corporate Responsibility Report

27 Mar 2023 07:30:00 By Nasdaq GlobeNewswire

Cytokinetics to Participate in Upcoming Investor Conferences

06 Mar 2023 16:00:00 By Nasdaq GlobeNewswire

Cytokinetics Presents Positive Results From Cohort 4 of REDWOOD-HCM and Long-Term Results From FOREST-HCM at the American College of Cardiology 72nd Annual Scientific Session

04 Mar 2023 10:00:00 By Nasdaq GlobeNewswire

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

02 Mar 2023 16:00:00 By Nasdaq GlobeNewswire

Cytokinetics Reports Fourth Quarter 2022 Financial Results

01 Mar 2023 16:00:00 By Nasdaq GlobeNewswire

Cytokinetics Receives Complete Response Letter From FDA for New Drug Application for Omecamtiv Mecarbil

28 Feb 2023 17:31:51 By Nasdaq GlobeNewswire

Cytokinetics Announces Three Upcoming Presentations at the American College of Cardiology 72nd Annual Scientific Session

24 Feb 2023 16:00:00 By Nasdaq GlobeNewswire

Cytokinetics Joins Global Initiative to Recognize International Rare Disease Day

22 Feb 2023 07:30:00 By Nasdaq GlobeNewswire

Cytokinetics to Announce Fourth Quarter Results on March 1, 2023

15 Feb 2023 16:00:00 By Nasdaq GlobeNewswire

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

01 Feb 2023 16:00:00 By Nasdaq GlobeNewswire

Cytokinetics Announces Recipients of Its Fifth Annual Communications Grant Program

30 Jan 2023 07:30:00 By Nasdaq GlobeNewswire

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

04 Jan 2023 16:00:00 By Nasdaq GlobeNewswire

Cytokinetics to Participate in the 41st Annual J.P. Morgan Healthcare Conference

03 Jan 2023 16:00:00 By Nasdaq GlobeNewswire

Cytokinetics Announces Outcome of FDA Advisory Committee Vote On Omecamtiv Mecarbil

13 Dec 2022 17:45:52 By Nasdaq GlobeNewswire

Cytokinetics Stock Trading Halted Today

13 Dec 2022 07:02:16 By Nasdaq GlobeNewswire

Cytokinetics Announces Availability of Briefing Documents for FDA Advisory Committee Meeting on Omecamtiv Mecarbil

09 Dec 2022 08:59:34 By Nasdaq GlobeNewswire

Cytokinetics Presents Data at the Virtual 33rd International Symposium on ALS/MND

08 Dec 2022 07:30:00 By Nasdaq GlobeNewswire

Cytokinetics Announces Initiation of Phase 1 Clinical Study of CK-3828136

07 Dec 2022 07:30:00 By Nasdaq GlobeNewswire